Otto A M, Müller C S G, Huff T, Hannappel E
Institute of Biochemistry University of Nuremberg-Erlangen, Fahrstr. 17, 91054 Erlangen, Germany.
J Cancer Res Clin Oncol. 2002 May;128(5):247-56. doi: 10.1007/s00432-002-0332-7. Epub 2002 Mar 19.
Elevated expression of the beta-thymosin isotypes T beta(4), T beta(10), and T(15) appears to be involved in the manifestation of a malignant phenotype of human tumor cells, including those of mammary carcinomas. This has evoked an interest in these peptides as diagnostic/prognostic tumor markers. If increased levels of beta-thymosins correspond to tumor malignancy, the question arises whether tumor growth inhibition induced by chemotherapeutic drugs would reduce their expression.
Two human breast cancer cell lines, the estrogen receptor(ER)-positive MCF-7 and the ER-negative MDA-MB231, were thus analyzed for the amount of beta-thymosin mRNAs by RNase protection assay and for the respective peptide levels by HPLC following different hormonal and drug treatments.
Both cell lines, growing in medium with 10% FCS, contain T beta(4) (400-500 fg/cell) and Tbeta(10) (about 100 fg/cell), but no T beta(15). Incubating MCF-7 cells with tamoxifen (1 microM) for 5 days resulted in about 80% growth inhibition and in reduction of intracellular T beta(4) and T beta(10) concentrations by about 40%. Levels of T beta(4) and T beta(10)-mRNA were reduced by about 60%. In contrast, cisplatin (2 microM) changed neither the peptide concentrations nor the mRNA levels of beta-thymosins, in spite of marked growth inhibition. In addition, no changes in beta-thymosin expression were observed in MDA-MB231 cells treated with either drug. MCF-7 cells maintained in estrogen-poor medium (10% horse serum) or stimulated to grow with estradiol (1 nM) had Tbeta(4) and T beta(10) concentrations reduced by about 30%, but changes in T beta(4)- and T beta(10)-mRNA levels did not correspond to those of the peptide.
Expression of T beta(4) and T beta(10) mRNAs and their peptides is differentially regulated and does not correlate with growth. Instead, reduced beta-thymosin expression may be linked to more intensive TRITC-phalloidin staining of F-actin lining the membrane at sites of intimate cell-cell contacts, while increased beta-thymosin levels appear in cells with more extensive substrate adhesion. This suggests that beta-thymosins play a role in cell surface dynamics.
β-胸腺素亚型Tβ(4)、Tβ(10)和T(15)的表达升高似乎与人类肿瘤细胞(包括乳腺癌细胞)恶性表型的表现有关。这引发了人们对这些肽作为诊断/预后肿瘤标志物的兴趣。如果β-胸腺素水平升高与肿瘤恶性程度相关,那么化疗药物诱导的肿瘤生长抑制是否会降低其表达就成了一个问题。
因此,通过核糖核酸酶保护试验分析了两种人乳腺癌细胞系,雌激素受体(ER)阳性的MCF-7和ER阴性的MDA-MB231中β-胸腺素mRNA的量,并在不同的激素和药物处理后通过高效液相色谱法分析了相应的肽水平。
两种细胞系在含10%胎牛血清的培养基中生长时,均含有Tβ(4)(400 - 500 fg/细胞)和Tβ(10)(约100 fg/细胞),但不含Tβ(15)。用他莫昔芬(1 μM)处理MCF-7细胞5天导致约80%的生长抑制,细胞内Tβ(4)和Tβ(10)浓度降低约40%。Tβ(4)和Tβ(10) - mRNA水平降低约60%。相比之下,顺铂(2 μM)尽管有明显的生长抑制作用,但既未改变β-胸腺素的肽浓度,也未改变其mRNA水平。此外,用这两种药物处理的MDA-MB231细胞中β-胸腺素表达均未观察到变化。在缺乏雌激素的培养基(10%马血清)中培养的MCF-7细胞或用雌二醇(1 nM)刺激生长的MCF-7细胞,其Tβ(4)和Tβ(10)浓度降低约30%,但Tβ(4)和Tβ(10) - mRNA水平的变化与肽的变化不对应。
Tβ(4)和Tβ(10) mRNA及其肽的表达受到不同调节,且与生长无关。相反,β-胸腺素表达降低可能与紧密细胞间接触部位膜内衬F-肌动蛋白的TRITC-鬼笔环肽染色增强有关,而β-胸腺素水平升高则出现在底物黏附更广泛的细胞中。这表明β-胸腺素在细胞表面动力学中起作用。